Cargando…

Automated tumor proportion score analysis for PD-L1 (22C3) expression in lung squamous cell carcinoma

Programmed cell death ligend-1 (PD-L1) expression by immunohistochemistry (IHC) assays is a predictive marker of anti-PD-1/PD-L1 therapy response. With the popularity of anti-PD-1/PD-L1 inhibitor drugs, quantitative assessment of PD-L1 expression becomes a new labor for pathologists. Manually counti...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jingxin, Zheng, Qiang, Mu, Xiao, Zuo, Yanfei, Xu, Bo, Jin, Yan, Wang, Yue, Tian, Hua, Yang, Yongguo, Xue, Qianqian, Huang, Ziling, Chen, Lijun, Gu, Bin, Hou, Xianxu, Shen, Linlin, Guo, Yan, Li, Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8342621/
https://www.ncbi.nlm.nih.gov/pubmed/34354151
http://dx.doi.org/10.1038/s41598-021-95372-1
_version_ 1783734110450089984
author Liu, Jingxin
Zheng, Qiang
Mu, Xiao
Zuo, Yanfei
Xu, Bo
Jin, Yan
Wang, Yue
Tian, Hua
Yang, Yongguo
Xue, Qianqian
Huang, Ziling
Chen, Lijun
Gu, Bin
Hou, Xianxu
Shen, Linlin
Guo, Yan
Li, Yuan
author_facet Liu, Jingxin
Zheng, Qiang
Mu, Xiao
Zuo, Yanfei
Xu, Bo
Jin, Yan
Wang, Yue
Tian, Hua
Yang, Yongguo
Xue, Qianqian
Huang, Ziling
Chen, Lijun
Gu, Bin
Hou, Xianxu
Shen, Linlin
Guo, Yan
Li, Yuan
author_sort Liu, Jingxin
collection PubMed
description Programmed cell death ligend-1 (PD-L1) expression by immunohistochemistry (IHC) assays is a predictive marker of anti-PD-1/PD-L1 therapy response. With the popularity of anti-PD-1/PD-L1 inhibitor drugs, quantitative assessment of PD-L1 expression becomes a new labor for pathologists. Manually counting the PD-L1 positive stained tumor cells is an obviously subjective and time-consuming process. In this paper, we developed a new computer aided Automated Tumor Proportion Scoring System (ATPSS) to determine the comparability of image analysis with pathologist scores. A three-stage process was performed using both image processing and deep learning techniques to mimic the actual diagnostic flow of the pathologists. We conducted a multi-reader multi-case study to evaluate the agreement between pathologists and ATPSS. Fifty-one surgically resected lung squamous cell carcinoma were prepared and stained using the Dako PD-L1 (22C3) assay, and six pathologists with different experience levels were involved in this study. The TPS predicted by the proposed model had high and statistically significant correlation with sub-specialty pathologists’ scores with Mean Absolute Error (MAE) of 8.65 (95% confidence interval (CI): 6.42–10.90) and Pearson Correlation Coefficient (PCC) of 0.9436 ([Formula: see text] ), and the performance on PD-L1 positive cases achieved by our method surpassed that of non-subspecialty and trainee pathologists. Those experimental results indicate that the proposed automated system can be a powerful tool to improve the PD-L1 TPS assessment of pathologists.
format Online
Article
Text
id pubmed-8342621
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-83426212021-08-10 Automated tumor proportion score analysis for PD-L1 (22C3) expression in lung squamous cell carcinoma Liu, Jingxin Zheng, Qiang Mu, Xiao Zuo, Yanfei Xu, Bo Jin, Yan Wang, Yue Tian, Hua Yang, Yongguo Xue, Qianqian Huang, Ziling Chen, Lijun Gu, Bin Hou, Xianxu Shen, Linlin Guo, Yan Li, Yuan Sci Rep Article Programmed cell death ligend-1 (PD-L1) expression by immunohistochemistry (IHC) assays is a predictive marker of anti-PD-1/PD-L1 therapy response. With the popularity of anti-PD-1/PD-L1 inhibitor drugs, quantitative assessment of PD-L1 expression becomes a new labor for pathologists. Manually counting the PD-L1 positive stained tumor cells is an obviously subjective and time-consuming process. In this paper, we developed a new computer aided Automated Tumor Proportion Scoring System (ATPSS) to determine the comparability of image analysis with pathologist scores. A three-stage process was performed using both image processing and deep learning techniques to mimic the actual diagnostic flow of the pathologists. We conducted a multi-reader multi-case study to evaluate the agreement between pathologists and ATPSS. Fifty-one surgically resected lung squamous cell carcinoma were prepared and stained using the Dako PD-L1 (22C3) assay, and six pathologists with different experience levels were involved in this study. The TPS predicted by the proposed model had high and statistically significant correlation with sub-specialty pathologists’ scores with Mean Absolute Error (MAE) of 8.65 (95% confidence interval (CI): 6.42–10.90) and Pearson Correlation Coefficient (PCC) of 0.9436 ([Formula: see text] ), and the performance on PD-L1 positive cases achieved by our method surpassed that of non-subspecialty and trainee pathologists. Those experimental results indicate that the proposed automated system can be a powerful tool to improve the PD-L1 TPS assessment of pathologists. Nature Publishing Group UK 2021-08-05 /pmc/articles/PMC8342621/ /pubmed/34354151 http://dx.doi.org/10.1038/s41598-021-95372-1 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Liu, Jingxin
Zheng, Qiang
Mu, Xiao
Zuo, Yanfei
Xu, Bo
Jin, Yan
Wang, Yue
Tian, Hua
Yang, Yongguo
Xue, Qianqian
Huang, Ziling
Chen, Lijun
Gu, Bin
Hou, Xianxu
Shen, Linlin
Guo, Yan
Li, Yuan
Automated tumor proportion score analysis for PD-L1 (22C3) expression in lung squamous cell carcinoma
title Automated tumor proportion score analysis for PD-L1 (22C3) expression in lung squamous cell carcinoma
title_full Automated tumor proportion score analysis for PD-L1 (22C3) expression in lung squamous cell carcinoma
title_fullStr Automated tumor proportion score analysis for PD-L1 (22C3) expression in lung squamous cell carcinoma
title_full_unstemmed Automated tumor proportion score analysis for PD-L1 (22C3) expression in lung squamous cell carcinoma
title_short Automated tumor proportion score analysis for PD-L1 (22C3) expression in lung squamous cell carcinoma
title_sort automated tumor proportion score analysis for pd-l1 (22c3) expression in lung squamous cell carcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8342621/
https://www.ncbi.nlm.nih.gov/pubmed/34354151
http://dx.doi.org/10.1038/s41598-021-95372-1
work_keys_str_mv AT liujingxin automatedtumorproportionscoreanalysisforpdl122c3expressioninlungsquamouscellcarcinoma
AT zhengqiang automatedtumorproportionscoreanalysisforpdl122c3expressioninlungsquamouscellcarcinoma
AT muxiao automatedtumorproportionscoreanalysisforpdl122c3expressioninlungsquamouscellcarcinoma
AT zuoyanfei automatedtumorproportionscoreanalysisforpdl122c3expressioninlungsquamouscellcarcinoma
AT xubo automatedtumorproportionscoreanalysisforpdl122c3expressioninlungsquamouscellcarcinoma
AT jinyan automatedtumorproportionscoreanalysisforpdl122c3expressioninlungsquamouscellcarcinoma
AT wangyue automatedtumorproportionscoreanalysisforpdl122c3expressioninlungsquamouscellcarcinoma
AT tianhua automatedtumorproportionscoreanalysisforpdl122c3expressioninlungsquamouscellcarcinoma
AT yangyongguo automatedtumorproportionscoreanalysisforpdl122c3expressioninlungsquamouscellcarcinoma
AT xueqianqian automatedtumorproportionscoreanalysisforpdl122c3expressioninlungsquamouscellcarcinoma
AT huangziling automatedtumorproportionscoreanalysisforpdl122c3expressioninlungsquamouscellcarcinoma
AT chenlijun automatedtumorproportionscoreanalysisforpdl122c3expressioninlungsquamouscellcarcinoma
AT gubin automatedtumorproportionscoreanalysisforpdl122c3expressioninlungsquamouscellcarcinoma
AT houxianxu automatedtumorproportionscoreanalysisforpdl122c3expressioninlungsquamouscellcarcinoma
AT shenlinlin automatedtumorproportionscoreanalysisforpdl122c3expressioninlungsquamouscellcarcinoma
AT guoyan automatedtumorproportionscoreanalysisforpdl122c3expressioninlungsquamouscellcarcinoma
AT liyuan automatedtumorproportionscoreanalysisforpdl122c3expressioninlungsquamouscellcarcinoma